Vulval Lichen Sclerosus (VLS) is a chronic inflammatory dermatosis that significantly impacts the quality of life. We report 2 cases of severe treatment-resistant VLS treated with subcutaneous adalimumab. One patient showed modest clinical improvement with no significant improvement in quality-of-life measures. The second patient showed a significant improvement in both clinical and quality-of-life measures. Both patients achieved optimal control with a maintenance dosing of 40 mg subcutaneously weekly. Adalimumab may be a treatment option for recalcitrant VLS; however, clinical trials are required to confirm efficacy for this indication.
Keywords: adalimumab; antibodies; female; humanised; humans; lichen sclerosus et atrophicus/therapy; monoclonal; vulvar diseases/drug therapy; vulvar lichen sclerosus.
© 2022 Australasian College of Dermatologists.